IMNM - Study finds no benefit of convalescent plasma as COVID-19 treatment

A new study has found that patients with COVID-19 given convalescent plasma did not show a survival benefit compared to those on standard of care.The study, which has yet to be peer reviewed, found that there was no difference in 28-day mortality between the two groups.Results also showed that convalescent plasma had no significant effect on hospital discharge within 28 days."Among patients hospitalized with COVID-19, high-titer convalescent plasma did not improve survival or other prespecified clinical outcomes," the authors concluded.Convalescent plasma is a component of blood that is derived from those who have recovered from COVID-19.The impact of the findings are having mixed results on several pharma and biotech companies working on convalescent plasma as therapy for COVID-19.Immunome (IMNM), which has biosynthetic convalescent plasma candidate IMM-BCP-01 slated for an IND filing in the first half of the year, is down 3% to $29.65.Takeda (TAK), which is part of the CoVIg-19 Plasma Alliance,

For further details see:

Study finds no benefit of convalescent plasma as COVID-19 treatment